{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,27]],"date-time":"2026-09-27T00:59:13Z","timestamp":1790470753504,"version":"4.1.0"},"reference-count":80,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,7,11]],"date-time":"2026-07-11T00:00:00Z","timestamp":1783728000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100006393","name":"University of Granada","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100006393","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["International Journal of Biological Macromolecules"],"published-print":{"date-parts":[[2026,10]]},"DOI":"10.1016\/j.ijbiomac.2026.153486","type":"journal-article","created":{"date-parts":[[2026,7,10]],"date-time":"2026-07-10T23:20:39Z","timestamp":1783725639000},"page":"153486","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Preclinical evidence for cytokine-based immunotherapy in pancreatic cancer treatment: A systematic review"],"prefix":"10.1016","volume":"377","author":[{"given":"Jorge","family":"Rodr\u00edguez-Criado","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alfonso J.","family":"Corona-Castro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francisco","family":"Qui\u00f1onero","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jose","family":"Prados","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Consolacion","family":"Melguizo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ijbiomac.2026.153486_bb0005","first-page":"229","article-title":"Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"74","author":"Bray","year":"2024","journal-title":"CA Cancer J. Clin."},{"key":"10.1016\/j.ijbiomac.2026.153486_bb0010","article-title":"Cancer statistics, 2026","volume":"76","author":"Siegel","year":"2026","journal-title":"CA Cancer J. Clin."},{"key":"10.1016\/j.ijbiomac.2026.153486_bb0015","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1007\/s12029-025-01183-2","article-title":"Trends in the global incidence of pancreatic cancer and a brief review of its histologic and molecular subtypes","volume":"56","author":"Leiphrakpam","year":"2025","journal-title":"J. Gastrointest. Cancer"},{"key":"10.1016\/j.ijbiomac.2026.153486_bb0020","first-page":"10","article-title":"Cancer statistics, 2025","volume":"75","author":"Siegel","year":"2025","journal-title":"CA Cancer J. Clin."},{"key":"10.1016\/j.ijbiomac.2026.153486_bb0025","doi-asserted-by":"crossref","DOI":"10.1080\/08941939.2022.2129884","article-title":"Pancreatic cancer: a review of current treatment and novel therapies","volume":"36","author":"Kolbeinsson","year":"2023","journal-title":"J. Investig. Surg."},{"issue":"1","key":"10.1016\/j.ijbiomac.2026.153486_bb0030","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s13045-024-01561-6","article-title":"Current and future immunotherapeutic approaches in pancreatic cancer treatment","volume":"17","author":"Farhangnia","year":"2024","journal-title":"J. Hematol. Oncol."},{"key":"10.1016\/j.ijbiomac.2026.153486_bb0035","doi-asserted-by":"crossref","first-page":"2091","DOI":"10.1042\/CS20191211","article-title":"Emerging roles for the IL-6 family of cytokines in pancreatic cancer","volume":"134","author":"van Duijneveldt","year":"2020","journal-title":"Clin. Sci."},{"key":"10.1016\/j.ijbiomac.2026.153486_bb0040","doi-asserted-by":"crossref","DOI":"10.1016\/j.canlet.2024.216859","article-title":"Cancer-associated fibroblasts in pancreatic ductal adenocarcinoma therapy: challenges and opportunities","volume":"591","author":"Qin","year":"2024","journal-title":"Cancer Lett."},{"key":"10.1016\/j.ijbiomac.2026.153486_bb0045","doi-asserted-by":"crossref","DOI":"10.3390\/biomedicines10092116","article-title":"Inflammatory cytokine: an attractive target for cancer treatment","volume":"10","author":"Lee","year":"2022","journal-title":"Biomedicines"},{"key":"10.1016\/j.ijbiomac.2026.153486_bb0050","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1038\/s41698-024-00681-z","article-title":"Barriers and opportunities in pancreatic cancer immunotherapy","volume":"8","author":"Ju","year":"2024","journal-title":"NPJ Precis. Oncol."},{"key":"10.1016\/j.ijbiomac.2026.153486_bb0055","article-title":"The PRISMA 2020 statement: an updated guideline for reporting systematic reviews","volume":"372","author":"Page","year":"2021","journal-title":"BMJ"},{"key":"10.1016\/j.ijbiomac.2026.153486_bb0060","doi-asserted-by":"crossref","first-page":"1038","DOI":"10.1016\/j.prosdent.2022.05.019","article-title":"Development and validation of a risk-of-bias tool for assessing in vitro studies conducted in dentistry: the QUIN","volume":"131","author":"Sheth","year":"2024","journal-title":"J. Prosthet. Dent."},{"key":"10.1016\/j.ijbiomac.2026.153486_bb0065","doi-asserted-by":"crossref","DOI":"10.1186\/1471-2288-14-43","article-title":"SYRCLE\u2019s risk of bias tool for animal studies","volume":"14","author":"Hooijmans","year":"2014","journal-title":"BMC Med. Res. Methodol."},{"key":"10.1016\/j.ijbiomac.2026.153486_bb0070","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1002\/jrsm.1411","article-title":"Risk-of-bias VISualization (robvis): an R package and shiny web app for visualizing risk-of-bias assessments","volume":"12","author":"McGuinness","year":"2021","journal-title":"Res. Synth. Methods"},{"key":"10.1016\/j.ijbiomac.2026.153486_bb0075","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1016\/j.acuro.2018.01.010","article-title":"Methodology of a systematic review","volume":"42","author":"Linares-Espin\u00f3s","year":"2018","journal-title":"Actas Urol. Esp."},{"key":"10.1016\/j.ijbiomac.2026.153486_bb0080","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1007\/s00262-025-04072-6","article-title":"Oncolytic adenovirus encoding variant interleukin-2 combined with chemotherapy enables PD-L1 inhibition in pancreatic cancer models","volume":"74","author":"Pakola","year":"2025","journal-title":"Cancer Immunol. Immunother."},{"key":"10.1016\/j.ijbiomac.2026.153486_bb0085","article-title":"Oncolytic HSV-1 expressing FLT3L kills melanoma, glioblastoma, and pancreatic cancer cells in vitro and induces immunogenic cell death","volume":"33","author":"Tuyaerts","year":"2025","journal-title":"Mol. Ther. Oncol."},{"key":"10.1016\/j.ijbiomac.2026.153486_bb0090","doi-asserted-by":"crossref","DOI":"10.1016\/j.isci.2025.113053","article-title":"Interferon-\u03b1 and thymosin-\u03b11 plus tislelizumab enhance CD8+ T cell cytotoxicity toward pancreatic ductal adenocarcinoma","volume":"28","author":"Deng","year":"2025","journal-title":"iScience"},{"key":"10.1016\/j.ijbiomac.2026.153486_bb0095","doi-asserted-by":"crossref","DOI":"10.1016\/j.biopha.2022.114212","article-title":"TGF-\u03b22 antisense oligonucleotide enhances T-cell mediated anti-tumor activities by IL-2 via attenuation of fibrotic reaction in a humanized mouse model of pancreatic ductal adenocarcinoma","volume":"159","author":"Lee","year":"2023","journal-title":"Biomed. Pharmacother."},{"key":"10.1016\/j.ijbiomac.2026.153486_bb0100","doi-asserted-by":"crossref","DOI":"10.1016\/j.canlet.2022.215722","article-title":"Anti-IL-8 antibody activates myeloid cells and potentiates the anti-tumor activity of anti-PD-1 antibody in the humanized pancreatic cancer murine model","volume":"539","author":"Li","year":"2022","journal-title":"Cancer Lett."},{"key":"10.1016\/j.ijbiomac.2026.153486_bb0105","doi-asserted-by":"crossref","DOI":"10.1016\/j.omtn.2024.102350","article-title":"Integrating IL-12 mRNA nanotechnology with SBRT eliminates T cell exhaustion in preclinical models of pancreatic cancer","volume":"35","author":"Hughson","year":"2024","journal-title":"Mol. Ther. Nucleic Acids"},{"key":"10.1016\/j.ijbiomac.2026.153486_bb0110","doi-asserted-by":"crossref","DOI":"10.1126\/sciimmunol.adp3978","article-title":"Combined Flt3L and CD40 agonism restores dendritic cell\u2013driven T cell immunity in pancreatic cancer","volume":"10","author":"Hogg","year":"2025","journal-title":"Sci. Immunol."},{"key":"10.1016\/j.ijbiomac.2026.153486_bb0115","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2023.1165404","article-title":"IL-15 armoring enhances the antitumor efficacy of claudin 18.2-targeting CAR-T cells in syngeneic mouse tumor models","volume":"14","author":"Shi","year":"2023","journal-title":"Front. Immunol."},{"key":"10.1016\/j.ijbiomac.2026.153486_bb0120","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2024.1506632","article-title":"GM-CSF and IL-21-armed oncolytic vaccinia virus significantly enhances anti-tumor activity and synergizes with anti-PD1 immunotherapy in pancreatic cancer","volume":"15","author":"Xuan","year":"2025","journal-title":"Front. Immunol."},{"key":"10.1016\/j.ijbiomac.2026.153486_bb0125","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1016\/j.cytogfr.2025.11.003","article-title":"Targeting cytokines: reshaping the pancreatic tumor microenvironment","volume":"86","author":"Bandi","year":"2025","journal-title":"Cytokine Growth Factor Rev."},{"key":"10.1016\/j.ijbiomac.2026.153486_bb0130","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1016\/j.cytogfr.2026.01.005","article-title":"TGF-\u03b2\u2013YY1 signaling as a key driver of immune evasion in pancreatic cancer: therapeutic implications","volume":"88","author":"Ho","year":"2026","journal-title":"Cytokine Growth Factor Rev."},{"key":"10.1016\/j.ijbiomac.2026.153486_bb0135","doi-asserted-by":"crossref","DOI":"10.1016\/j.celrep.2025.116010","article-title":"A STAT3\/integrin axis accelerates pancreatic cancer initiation and progression","volume":"44","author":"Campos","year":"2025","journal-title":"Cell Rep."},{"key":"10.1016\/j.ijbiomac.2026.153486_bb0140","doi-asserted-by":"crossref","first-page":"874","DOI":"10.1053\/j.gastro.2023.05.038","article-title":"Transforming growth factor-\u03b2 blockade in pancreatic cancer enhances sensitivity to combination chemotherapy","volume":"165","author":"Qiang","year":"2023","journal-title":"Gastroenterology"},{"key":"10.1016\/j.ijbiomac.2026.153486_bb0145","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.182766","article-title":"Targeting heterogeneous tumor microenvironments in pancreatic cancer mouse models of metastasis by TGF-\u03b2 depletion","volume":"9","author":"Chen","year":"2024","journal-title":"JCI Insight"},{"key":"10.1016\/j.ijbiomac.2026.153486_bb0150","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1007\/s11605-021-05087-x","article-title":"TGF-\u03b2 alters the proportion of infiltrating immune cells in a pancreatic ductal adenocarcinoma","volume":"26","author":"Trebska-McGowan","year":"2022","journal-title":"J. Gastrointest. Surg."},{"key":"10.1016\/j.ijbiomac.2026.153486_bb0155","doi-asserted-by":"crossref","first-page":"748","DOI":"10.1186\/s12951-025-03795-z","article-title":"Mitochondrial-targeted photodynamic therapy combined with TGF-\u03b2 inhibition potentiates anti-PD-1 therapy in pancreatic ductal adenocarcinoma","volume":"23","author":"Xu","year":"2025","journal-title":"J. Nanobiotechnol."},{"key":"10.1016\/j.ijbiomac.2026.153486_bb0160","doi-asserted-by":"crossref","DOI":"10.1002\/advs.202105240","article-title":"Local release of TGF-\u03b2 inhibitor modulates tumor-associated neutrophils and enhances pancreatic cancer response to combined irreversible electroporation and immunotherapy","volume":"9","author":"Peng","year":"2022","journal-title":"Adv. Sci."},{"key":"10.1016\/j.ijbiomac.2026.153486_bb0165","doi-asserted-by":"crossref","first-page":"5121","DOI":"10.1039\/D0BM00916D","article-title":"Co-inhibition of the TGF-\u03b2 pathway and the PD-L1 checkpoint by pH-responsive clustered nanoparticles for pancreatic cancer microenvironment regulation and anti-tumor immunotherapy","volume":"8","author":"Wang","year":"2020","journal-title":"Biomater. Sci."},{"key":"10.1016\/j.ijbiomac.2026.153486_bb0170","doi-asserted-by":"crossref","DOI":"10.1016\/j.biomaterials.2024.122888","article-title":"An innovative strategy harnessing self-activating CAR-NK cells to mitigate TGF-\u03b21-driven immune suppression","volume":"314","author":"Shin","year":"2025","journal-title":"Biomaterials"},{"key":"10.1016\/j.ijbiomac.2026.153486_bb0175","doi-asserted-by":"crossref","DOI":"10.1016\/j.canlet.2023.216457","article-title":"A novel role of TGFBI in macrophage polarization and macrophage-induced pancreatic cancer growth and therapeutic resistance","volume":"578","author":"Zhou","year":"2023","journal-title":"Cancer Lett."},{"key":"10.1016\/j.ijbiomac.2026.153486_bb0180","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1158\/2767-9764.CRC-23-0019","article-title":"Intertumoral differences dictate the outcome of TGF-\u03b2 blockade on the efficacy of Viro-immunotherapy","volume":"3","author":"Groeneveldt","year":"2023","journal-title":"Cancer Res. Commun."},{"key":"10.1016\/j.ijbiomac.2026.153486_bb0185","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.153242","article-title":"Targeting TNF-\u03b1\u2013producing macrophages activates antitumor immunity in pancreatic cancer via IL-33 signaling","volume":"7","author":"Dixit","year":"2022","journal-title":"JCI Insight"},{"key":"10.1016\/j.ijbiomac.2026.153486_bb0190","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1186\/s40164-025-00607-w","article-title":"Distinct response to IL-1\u03b2 blockade in liver- and lung-specific metastasis mouse models of pancreatic cancer with heterogeneous tumor microenvironments","volume":"14","author":"Chen","year":"2025","journal-title":"Exp. Hematol. Oncol."},{"key":"10.1016\/j.ijbiomac.2026.153486_bb0195","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.155006","article-title":"Dual IL-6 and CTLA-4 blockade regresses pancreatic tumors in a T cell- and CXCR3-dependent manner","volume":"8","author":"Ware","year":"2023","journal-title":"JCI Insight"},{"key":"10.1016\/j.ijbiomac.2026.153486_bb0200","doi-asserted-by":"crossref","DOI":"10.1084\/jem.20190354","article-title":"Interleukin-17-induced neutrophil extracellular traps mediate resistance to checkpoint blockade in pancreatic cancer","volume":"217","author":"Zhang","year":"2020","journal-title":"J. Exp. Med."},{"key":"10.1016\/j.ijbiomac.2026.153486_bb0205","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1038\/s41392-020-0144-8","article-title":"PD-L1 is a direct target of cancer-FOXP3 in pancreatic ductal adenocarcinoma (PDAC), and combined immunotherapy with antibodies against PD-L1 and CCL5 is effective in the treatment of PDAC","volume":"5","author":"Wang","year":"2020","journal-title":"Signal Transduct. Target. Ther."},{"key":"10.1016\/j.ijbiomac.2026.153486_bb0210","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2019-000308","article-title":"Interferon gamma inhibits CXCL8\u2013CXCR2 axis mediated tumor-associated macrophages tumor trafficking and enhances anti-PD1 efficacy in pancreatic cancer","volume":"8","author":"Zhang","year":"2020","journal-title":"J. Immunother. Cancer"},{"key":"10.1016\/j.ijbiomac.2026.153486_bb0215","doi-asserted-by":"crossref","DOI":"10.1084\/jem.20190354","article-title":"Interleukin-17\u2013induced neutrophil extracellular traps mediate resistance to checkpoint blockade in pancreatic cancer","volume":"217","author":"Zhang","year":"2020","journal-title":"J. Exp. Med."},{"key":"10.1016\/j.ijbiomac.2026.153486_bb0220","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2024-008989","article-title":"rhIL-7-hyFc, a long-acting interleukin-7, improves efficacy of CAR-T cell therapy in solid tumors","volume":"12","author":"Li","year":"2024","journal-title":"J. Immunother. Cancer"},{"key":"10.1016\/j.ijbiomac.2026.153486_bb0225","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2025.1618404","article-title":"IL-7 armed binary CAR T cell strategy to augment potency against solid tumors","volume":"16","author":"Torres Chavez","year":"2025","journal-title":"Front. Immunol."},{"key":"10.1016\/j.ijbiomac.2026.153486_bb0230","doi-asserted-by":"crossref","first-page":"2503","DOI":"10.1007\/s00262-021-02853-3","article-title":"Enhanced anti-tumor efficacy of IL-7\/CCL19-producing human CAR-T cells in orthotopic and patient-derived xenograft tumor models","volume":"70","author":"Goto","year":"2021","journal-title":"Cancer Immunol. Immunother."},{"key":"10.1016\/j.ijbiomac.2026.153486_bb0235","doi-asserted-by":"crossref","first-page":"2514","DOI":"10.1158\/2767-9764.CRC-24-0226","article-title":"Therapeutic efficacy of IL7\/CCL19-expressing CAR-T cells in intractable solid tumor models of glioblastoma and pancreatic cancer","volume":"4","author":"Ohta","year":"2024","journal-title":"Cancer Res. Commun."},{"key":"10.1016\/j.ijbiomac.2026.153486_bb0240","doi-asserted-by":"crossref","DOI":"10.1073\/pnas.2517786122","article-title":"Targeting orthotopic and metastatic pancreatic cancer with allogeneic stem cell\u2013engineered mesothelin-redirected CAR-NKT cells","volume":"122","author":"Li","year":"2025","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.ijbiomac.2026.153486_bb0245","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2021-003923","article-title":"Natural killer T cell immunotherapy combined with IL-15-expressing oncolytic virotherapy and PD-1 blockade mediates pancreatic tumor regression","volume":"10","author":"Nelson","year":"2022","journal-title":"J. Immunother. Cancer"},{"key":"10.1016\/j.ijbiomac.2026.153486_bb0250","doi-asserted-by":"crossref","first-page":"847","DOI":"10.1158\/2326-6066.CIR-24-0758","article-title":"IL-15 complex enhances agonistic anti-CD40 + anti-PDL1 by correcting the T-bet to Tox ratio in CD8+ T cells infiltrating pancreatic ductal adenocarcinoma","volume":"13","author":"Schmiechen","year":"2025","journal-title":"Cancer Immunol. Res."},{"key":"10.1016\/j.ijbiomac.2026.153486_bb0255","doi-asserted-by":"crossref","DOI":"10.1002\/cti2.1165","article-title":"Novel combination immunotherapy for pancreatic cancer: potent anti-tumor effects with CD40 agonist and interleukin-15 treatment","volume":"9","author":"Van Audenaerde","year":"2020","journal-title":"Clin. Transl. Immunol."},{"key":"10.1016\/j.ijbiomac.2026.153486_bb0260","doi-asserted-by":"crossref","first-page":"3228","DOI":"10.1093\/jimmun\/vkaf314","article-title":"IL-15 complex enhances therapeutic efficacy of anti-PD-L1 in a T cell\u2013dependent and NK cell\u2013independent manner in a murine model of pancreatic ductal adenocarcinoma","volume":"214","author":"Burrack","year":"2025","journal-title":"J. Immunol."},{"key":"10.1016\/j.ijbiomac.2026.153486_bb0265","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2023.1171083","article-title":"An oncolytic adenovirus coding for a variant interleukin 2 cytokine improves response to chemotherapy through enhancement of effector lymphocyte cytotoxicity, fibroblast compartment modulation and mitotic slippage","volume":"14","author":"Pakola","year":"2023","journal-title":"Front. Immunol."},{"key":"10.1016\/j.ijbiomac.2026.153486_bb0270","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1186\/s13046-024-03238-x","article-title":"Antibody-based delivery of interleukin-2 modulates the immunosuppressive tumor microenvironment and achieves cure in pancreatic ductal adenocarcinoma syngeneic mice","volume":"44","author":"Carbone","year":"2025","journal-title":"J. Exp. Clin. Cancer Res."},{"key":"10.1016\/j.ijbiomac.2026.153486_bb0275","doi-asserted-by":"crossref","DOI":"10.1126\/sciadv.adx2984","article-title":"Combined innate immune cell therapy, tumor-specific antibody, and radiation prompt antitumor response in pancreatic cancer models","volume":"11","author":"Rahman","year":"2025","journal-title":"Sci. Adv."},{"key":"10.1016\/j.ijbiomac.2026.153486_bb0280","doi-asserted-by":"crossref","first-page":"808","DOI":"10.1080\/08820139.2020.1765795","article-title":"Microspheres encapsulating immunotherapy agents target the tumor-draining lymph node in pancreatic ductal adenocarcinoma","volume":"49","author":"Han","year":"2020","journal-title":"Immunol. Investig."},{"key":"10.1016\/j.ijbiomac.2026.153486_bb0285","doi-asserted-by":"crossref","first-page":"57546","DOI":"10.1021\/acsami.5c15319","article-title":"Oxygen-delivering semiconducting polymer Nanocytokines for Sono-induced combination immunotherapy of Orthotopic pancreatic Cancer","volume":"17","author":"Zhan","year":"2025","journal-title":"ACS Appl. Mater. Interfaces"},{"key":"10.1016\/j.ijbiomac.2026.153486_bb0290","article-title":"Oncolytic adeno-immunotherapy improves allogeneic adoptive HER2.CAR-NK function against pancreatic ductal adenocarcinoma","volume":"33","author":"Biegert","year":"2025","journal-title":"Mol. Ther. Oncol."},{"key":"10.1016\/j.ijbiomac.2026.153486_bb0295","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2025.1664289","article-title":"IL-12-armed oncolytic HSV-2 enhances CAR T cell efficacy against pancreatic cancer in xenografted models","volume":"16","author":"Xu","year":"2026","journal-title":"Front. Immunol."},{"key":"10.1016\/j.ijbiomac.2026.153486_bb0300","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2025-013175","article-title":"Oncolytic virus-induced IL-1\u03b2+ monocyte-IL-6+ CAF axis suppresses dendritic cell-mediated antitumor immunity in pancreatic cancer","volume":"13","author":"Li","year":"2025","journal-title":"J. Immunother. Cancer"},{"key":"10.1016\/j.ijbiomac.2026.153486_bb0305","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2020-001624","article-title":"A systemically deliverable vaccinia virus with increased capacity for intertumoral and intratumoral spread effectively treats pancreatic cancer","volume":"9","author":"Marelli","year":"2021","journal-title":"J. Immunother. Cancer"},{"key":"10.1016\/j.ijbiomac.2026.153486_bb0310","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2024-010341","article-title":"Novel oncolytic vaccinia virus armed with interleukin-27 is a potential therapeutic agent for the treatment of murine pancreatic cancer","volume":"13","author":"Jia","year":"2025","journal-title":"J. Immunother. Cancer"},{"key":"10.1016\/j.ijbiomac.2026.153486_bb0315","doi-asserted-by":"crossref","DOI":"10.3390\/cells11233839","article-title":"CAR triggered release of type-1 interferon limits CAR T-cell activities by an artificial negative autocrine loop","volume":"11","author":"Harrer","year":"2022","journal-title":"Cells"},{"key":"10.1016\/j.ijbiomac.2026.153486_bb0320","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1038\/s41392-025-02158-2","article-title":"Neoleukin-2\/15-armored CAR-NK cells sustain superior therapeutic efficacy in solid tumors via c-Myc\/NRF1 activation","volume":"10","author":"Luo","year":"2025","journal-title":"Signal Transduct. Target. Ther."},{"key":"10.1016\/j.ijbiomac.2026.153486_bb0325","article-title":"Induced expression of CCL19 promotes the anti-tumor ability of CAR-T cells by increasing their infiltration ability","volume":"13","author":"Hu","year":"2022","journal-title":"Front. Immunol."},{"key":"10.1016\/j.ijbiomac.2026.153486_bb0330","doi-asserted-by":"crossref","first-page":"2254","DOI":"10.1016\/j.cell.2025.12.049","article-title":"Hallmarks of cancer\u2014then and now, and beyond","volume":"189","author":"Hanahan","year":"2026","journal-title":"Cell"},{"key":"10.1016\/j.ijbiomac.2026.153486_bb0335","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1146\/annurev-pathmechdis-031621-024600","article-title":"Tumor microenvironment in pancreatic Cancer pathogenesis and therapeutic resistance","volume":"18","author":"Sherman","year":"2023","journal-title":"Annu. Rev. Pathol."},{"key":"10.1016\/j.ijbiomac.2026.153486_bb0340","doi-asserted-by":"crossref","DOI":"10.3390\/biom15020275","article-title":"The oncoprotein mucin 1 in pancreatic cancer onset and progression: potential clinical implications","volume":"15","author":"Dieli","year":"2025","journal-title":"Biomolecules"},{"key":"10.1016\/j.ijbiomac.2026.153486_bb0345","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1016\/j.cytogfr.2026.01.009","article-title":"Cytokine circuitry in pancreatic cancer: targets for overcoming immune checkpoint inhibitor resistance in PDAC","volume":"88","author":"Suresh","year":"2026","journal-title":"Cytokine Growth Factor Rev."},{"key":"10.1016\/j.ijbiomac.2026.153486_bb0350","doi-asserted-by":"crossref","DOI":"10.3390\/cancers12082274","article-title":"Mechanisms of T-cell exhaustion in pancreatic cancer","volume":"12","author":"Saka","year":"2020","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.ijbiomac.2026.153486_bb0355","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1158\/2326-6066.CIR-19-0373","article-title":"Assessing the magnitude of immunogenic cell death following chemotherapy and irradiation reveals a new strategy to treat pancreatic cancer","volume":"8","author":"Ye","year":"2020","journal-title":"Cancer Immunol. Res."},{"key":"10.1016\/j.ijbiomac.2026.153486_bb0360","doi-asserted-by":"crossref","first-page":"921","DOI":"10.1007\/s40264-014-0226-z","article-title":"Side effects of cytokines approved for therapy","volume":"37","author":"Baldo","year":"2014","journal-title":"Drug Saf."},{"key":"10.1016\/j.ijbiomac.2026.153486_bb0365","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1038\/s41424-018-0008-5","article-title":"Plasma inflammatory cytokines and survival of pancreatic cancer patients","volume":"9","author":"Babic","year":"2018","journal-title":"Clin. Transl. Gastroenterol."},{"key":"10.1016\/j.ijbiomac.2026.153486_bb0370","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1038\/s41571-020-0363-5","article-title":"The tumour microenvironment in pancreatic cancer - clinical challenges and opportunities","volume":"17","author":"Ho","year":"2020","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"10.1016\/j.ijbiomac.2026.153486_bb0375","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2023-007725","article-title":"First-in-human phase I\/Ib study of NIZ985, a recombinant heterodimer of IL-15 and IL-15R\u03b1, as a single agent and in combination with spartalizumab in patients with advanced and metastatic solid tumors","volume":"11","author":"Leidner","year":"2023","journal-title":"J. Immunother. Cancer"},{"key":"10.1016\/j.ijbiomac.2026.153486_bb0380","doi-asserted-by":"crossref","first-page":"28960","DOI":"10.1073\/pnas.2013644117","article-title":"CXCR4 inhibition in human pancreatic and colorectal cancers induces an integrated immune response","volume":"117","author":"Biasci","year":"2020","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.ijbiomac.2026.153486_bb0385","doi-asserted-by":"crossref","first-page":"1150","DOI":"10.1093\/bjs\/znac272","article-title":"Impact of classical and basal-like molecular subtypes on overall survival in resected pancreatic cancer in the SPACIOUS-2 multicentre study","volume":"109","author":"Suurmeijer","year":"2022","journal-title":"Br. J. Surg."},{"key":"10.1016\/j.ijbiomac.2026.153486_bb0390","doi-asserted-by":"crossref","first-page":"1129","DOI":"10.1016\/S2468-1253(23)00207-8","article-title":"The immunological landscape in pancreatic ductal adenocarcinoma and overcoming resistance to immunotherapy","volume":"8","author":"Hilmi","year":"2023","journal-title":"Lancet Gastroenterol. Hepatol."},{"key":"10.1016\/j.ijbiomac.2026.153486_bb0395","doi-asserted-by":"crossref","DOI":"10.1002\/adbi.201900236","article-title":"Advances in targeted therapy and immunotherapy for pancreatic cancer","volume":"5","author":"Liu","year":"2021","journal-title":"Adv. Biol."},{"key":"10.1016\/j.ijbiomac.2026.153486_bb5000","first-page":"e1230","article-title":"PRISMA2020: An R package and Shiny app for producing PRISMA 2020-compliant flow diagrams, with interactivity for optimized digital transparency and Open Synthesis","volume":"18","author":"Haddaway","year":"2022","journal-title":"Campbell Syst. Rev."}],"container-title":["International Journal of Biological Macromolecules"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0141813026034318?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0141813026034318?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,9,27]],"date-time":"2026-09-27T00:24:23Z","timestamp":1790468663000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0141813026034318"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10]]},"references-count":80,"alternative-id":["S0141813026034318"],"URL":"https:\/\/doi.org\/10.1016\/j.ijbiomac.2026.153486","relation":{},"ISSN":["0141-8130"],"issn-type":[{"value":"0141-8130","type":"print"}],"subject":[],"published":{"date-parts":[[2026,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Preclinical evidence for cytokine-based immunotherapy in pancreatic cancer treatment: A systematic review","name":"articletitle","label":"Article Title"},{"value":"International Journal of Biological Macromolecules","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ijbiomac.2026.153486","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"153486"}}